Tandem Diabetes raises FY18 sales view $150M-$158M from $140M-$148M
Revenue consensus $146.75M. Tandem Diabetes Care announced that it has increased its 2018 sales guidance to $150M to $158 million, from $140M to $148M, following continued strong domestic sales in Q3 and the recent launch of the t:slim X2 Insulin Pump in select international markets. Compared to 2017 sales of approximately $108M, the revised guidance range represents annual sales growth of 39% o 47%. The revised sales guidance includes a projected $7M to $8M of sales in select geographies outside of the United States, which commenced in August 2018. Sales, training and customer service outside of the United States are being provided by regional distribution partners, except in Canada. The t:slim X2 Insulin Pump is currently under review by Health Canada. The Company is planning to launch in Canada in the fourth quarter, subject to obtaining regulatory approval.